修订版京都标准与导管内乳头状黏液性肿瘤患者恶性肿瘤风险
该研究纳入2000-2021年诊断的3336例导管内乳头状黏液性肿瘤(IPMN)患者,验证修订版京都标准对胰腺癌短期(≤6个月)和长期风险的分层能力。短期分析中,高危征象组胰腺癌患病率为49%,担忧特征组为1.3%,无危险因素组为0.05%。长期分析中,主胰管直径5-9.9 mm、急性胰腺炎和IPMN生长速率2.5 mm/y与胰腺癌高发生率相关,多变量子分布风险比分别为3.46、5.65和3.83。
要点
- 高危征象组短期胰腺癌患病率为49%,担忧特征组为1.3%,无危险因素组为0.05%。
- 主胰管直径5-9.9 mm、急性胰腺炎、IPMN生长速率2.5 mm/y与长期胰腺癌高发生率相关。
- 基线担忧特征数量增加与胰腺癌患病率和发生率升高相关(Ptrend < .001)。
核心结论
- 修订版京都标准能较好地对IPMN患者胰腺癌诊断的短期和长期风险进行分层,可能有助于个体化管理。
研究设计与样本
- 研究纳入2000-2021年诊断的3336例IPMN患者,分析短期(≤6个月)和长期胰腺癌诊断风险。
- 采用多变量竞争风险比例风险回归模型计算胰腺癌长期发病的子分布风险比,并校正潜在混杂因素。
主要发现
- 短期分析中,胰腺癌主要见于高危征象IPMN,患病率49%;担忧特征IPMN为1.3%,无危险因素IPMN为0.05%。
- 长期分析中,主胰管直径5-9.9 mm、急性胰腺炎和IPMN生长速率2.5 mm/y与高发生率相关,多变量子分布风险比分别为3.46(95%CI 2.04-5.89)、5.65(95%CI 1.86-17.2)和3.83(95%CI 2.14-6.86)。
- 基线担忧特征数量增加与胰腺癌患病率和发生率升高相关(Ptrend < .001)。
- 与无阳性特征相比,有1、2和3-4个担忧特征的患者胰腺癌发病多变量子分布风险比分别为1.43(95%CI 0.93-2.19)、2.17(95%CI 1.17-4.05)和10.1(95%CI 4.20-24.5)。
关键数值与推荐
- 高危征象IPMN短期胰腺癌患病率为49%,担忧特征IPMN为1.3%,无危险因素IPMN为0.05%。
- 主胰管直径5-9.9 mm的多变量子分布风险比为3.46(95%CI 2.04-5.89)。
- 急性胰腺炎的多变量子分布风险比为5.65(95%CI 1.86-17.2)。
- IPMN生长速率2.5 mm/y的多变量子分布风险比为3.83(95%CI 2.14-6.86)。
- 与无阳性特征相比,1、2和3-4个担忧特征的多变量子分布风险比分别为1.43(95%CI 0.93-2.19)、2.17(95%CI 1.17-4.05)和10.1(95%CI 4.20-24.5)。
临床怎么用
- 修订版京都标准可用于对IPMN患者胰腺癌短期和长期风险进行分层,可能为个体化管理提供信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The revised Kyoto guidelines have a new catalog of high-risk stigmata and worrisome features for the risk stratification of intraductal papillary mucinous neoplasms (IPMNs). We aimed to validate the stratification system in terms of short- and long-term risks of pancreatic carcinoma. METHODS: We included 3336 patients diagnosed with IPMNs in 2000-2021 and examined short-term (≤6 months) and long-term risks of pancreatic carcinoma diagnosis. We used the multivariable competing-risks proportional hazards regression model to calculate subdistribution hazard ratios for long-term incidence of pancreatic carcinoma with adjustment for potential confounders. RESULTS: In short-term analyses, pancreatic carcinomas were prevalent predominantly in IPMNs with high-risk stigmata (49% vs 1.3% and 0.05% in IPMNs with worrisome features and no risk factors, respectively). In long-term analyses of worrisome features, the main pancreatic duct diameter of 5-9.9 mm, acute pancreatitis, and IPMN growth rate of 2.5 mm/y were associated with a high incidence with multivariable subdistribution hazard ratios of 3.46 (95% confidence interval [CI], 2.04-5.89), 5.65 (95% CI, 1.86-17.2), and 3.83 (95% CI, 2.14-6.86), respectively. An increasing number of worrisome features at baseline was associated with a higher prevalence and incidence of pancreatic carcinoma (Ptrend < .001). Patients with 1, 2, and 3-4 worrisome features had multivariable subdistribution hazard ratios for pancreatic cancer incidence of 1.43 (95% CI, 0.93-2.19), 2.17 (95% CI, 1.17-4.05), and 10.1 (95% CI, 4.20-24.5), respectively (vs no positive feature). CONCLUSIONS: The revised Kyoto criteria stratify IPMN patients well in terms of the short- and long-term risks of pancreatic carcinoma diagnosis, potentially informing personalized patient management.
引用
- Hamada T, Oyama H, Tange S, et al. The Revised Kyoto Criteria and Risk of Malignancy Among Patients With Intraductal Papillary Mucinous Neoplasms. Clin Gastroenterol Hepatol. 2024. PMID: 38880125. doi:10.1016/j.cgh.2024.05.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。